CurveBeam AI Limited (CVB) Fair Value & Analysis
Healthcare · AU · Market cap A$8.2M
Fair value as of: Jul 12, 2026
From 1 valuation models · updated 29 days ago
Share price +5.9% over the past month.
Below-average quality, currently priced close to our fair value.
What matters now
- The price sits close to our fair value, market and models broadly agree here, little valuation tension.
- Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Price vs Fair Value (3 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 12, 2026.
How to read this chart
36‑month range A$0.0160 – A$0.5000 · fair‑value band A$0.0178 – A$0.0221 · the A$0.0180 price screens above the A$0.0170 fair value. Dashed = 300-day average. As of Jul 12, 2026.
Analysis
CurveBeam AI Limited (CVB) currently trades at A$0.0180, while our model-based Fair Value estimate is A$0.0170, implying the stock looks roughly 5.6% fairly valued today. The Quality Score stands at 37/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: low).
Trailing-twelve-month revenue stands at A$12.2M. Revenue grew 1.1% year over year. It earns a return on equity of -41.8%. Net debt stands at A$8.6M. Fundamentals as of Jul 12, 2026
Our scenario range runs from A$0.0178 (bear case) to A$0.0221 (bull case); at A$0.0180, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. For context, the median of 10 Healthcare peers we cover trades at -22% fair-value upside, at -6%, CVB screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 1 models by family
Notify me when CVB reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 12, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 36 · Market factors (momentum, volatility) 0
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
CurveBeam AI Limited engages in the development and manufacture of point-of care specialized weight bearing medical imaging equipment in Europe, North America, and Australia.
Full company description
CurveBeam AI Limited engages in the development and manufacture of point-of care specialized weight bearing medical imaging equipment in Europe, North America, and Australia. The company offers HiRise for bilateral weight bearing CT imaging; LineUP, a bilateral, weight bearing CT imaging of the knees and lower extremities for orthpedic practices; pedCAT Premium and pedCAT for imaging of the foot and ankle; InReach, a point-of-care extremity CT imaging which assess the distal extremities with 3D clarity at a fraction of the dose; and CubeVue Software visualization tools. It also provides software CurveBeam AI Autometrics for automatically segment foot and ankle datasets; Axiometrics, provides a semi-automatic measurement of the axes of rotation of the hip, femur, knee, and ankle; and TALAS, a measurement tool that semi-automatically calculate hindfoot alignment based on reproducible three-dimensional anatomical landmarks. In addition, the company offers custom web-based cloud platform; and OSSView. The company was incorporated in 2009 and is headquartered in Hatfield, Pennsylvania.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
CurveBeam AI Limited reported revenue of A$12.1M in FY2025 versus A$7.2M in FY2021, a compound +13.9%/yr. Reported net income was −A$16.8M in FY2025.
Watch CVB: get an alert when its fair value changes →
Peer Group
Medical Devices · 352 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Devices median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Jul 12, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Abbott Laboratories, ABT | $100.68 | $74.79 | -26% |
| Stryker Corporation SYK | $316.44 | $186.28 | -41% |
| Medtronic plc MDT | $83.56 | $65.57 | -22% |
| Boston Scientific Corporation BSX | $43.04 | $38.44 | -11% |
| Edwards Lifesciences Corporation EW | $85.73 | $41.02 | -52% |
| Siemens Healthineers AG SHL | €34.59 | €33.87 | -2% |
| Shenzhen Mindray Bio-Medical Electronics Co 300760 | ¥149.43 | ¥147.63 | -1% |
| Shanghai United Imaging Healthcare Co 688271 | ¥109.00 | ¥43.60 | -60% |
| Demant A/S DEMANT | kr 276.60 | kr 161.17 | -42% |
| Getinge AB GETIB | kr 206.80 | kr 192.14 | -7% |
Compare CurveBeam AI Limited with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is CurveBeam AI Limited (CVB) overvalued or undervalued?
What is the fair value of CVB?
What is the quality score of CVB?
What is the revenue of CurveBeam AI Limited (CVB)?
What is the net profit margin of CVB?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track CurveBeam AI Limited and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.